Shopping Cart

Remove All
Your shopping cart is currently empty

GS-6201

GS-6201 (CVT-6883) is a selective antagonist of the adenosine A2B receptor, demonstrating high affinity and selectivity with a Ki of 22 nM for human adenosine A2B receptors.

Catalog No. T15418Cas No. 752222-83-6

Select Batch

Purity:99.74%

Resource Download

COA LCMS HPLC FNMR HNMR

GS-6201

Catalog No. T15418Cas No. 752222-83-6

GS-6201 (CVT-6883) is a selective antagonist of the adenosine A2B receptor, demonstrating high affinity and selectivity with a Ki of 22 nM for human adenosine A2B receptors.

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Pack Size	Price	Availability
1 mg	$37	In Stock
5 mg	$96	In Stock
10 mg	$155	In Stock
25 mg	$328	In Stock
50 mg	$522	In Stock
100 mg	$759	In Stock
1 mL x 10 mM (in DMSO)	$117	In Stock

Bulk & Custom

Add to Cart

Questions

Related Compound Libraries of "GS-6201"

Product Introduction

Bioactivity

Description	GS-6201 (CVT-6883) is a selective antagonist of the adenosine A2B receptor, demonstrating high affinity and selectivity with a Ki of 22 nM for human adenosine A2B receptors.
Targets&IC50	A2B:22 nM(Ki, human), A2A:3280 nM(Ki, human), A1:1940 nM(Ki, human), A3:1070 nM(Ki, human)
In vivo	GS-6201 (2 mg/kg; p.o.) treatment displays the Cmax, dAUC and t1/2 are 1110 ng/mL, 6500 ng h/mL, and 4.25 hours, respectively [1]. GS-6201 (4 mg/kg; i.p.; every 12 h for 14 days) obviously decreases IL-6, TNF-α, E-selectin, ICAM-1, and VCAM plasma levels. GS-6201 (4 mg/kg; i.p.; every 12 h for 14 days) causes an obvious attenuation of left and right ventricular enlargement and dysfunction at 7 days, which was maintained at 14 days and also at 28 days [2].
Alias	CVT-6883

Chemical Properties

Molecular Weight	446.43
Formula	C₂₁H₂₁F₃N₆O₂
Cas No.	752222-83-6

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

Solubility Information

DMSO: 30 mg/ml (67.2 mM), Sonication and heating to 60℃ are recommended.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.2400 mL	11.2000 mL	22.3999 mL	111.9996 mL
5 mM	0.4480 mL	2.2400 mL	4.4800 mL	22.3999 mL
10 mM	0.2240 mL	1.1200 mL	2.2400 mL	11.2000 mL
20 mM	0.1120 mL	0.5600 mL	1.1200 mL	5.6000 mL
50 mM	0.0448 mL	0.2240 mL	0.4480 mL	2.2400 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:

For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments

A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent

DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。

Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO TargetMol | reagent

(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.

Preparation method for in vivo formula: Take 50 μL DMSO TargetMol | reagent

main solution, add 300 μLPEG300 TargetMol | reagent

mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O TargetMol | reagent

mix well and clarify

For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc